107.5FM WCCN The Rock - The Coolest Station in the Nation
ESPN 92.3FM WOSQ
92.7FM WPKG
Memories 1370AM 98.5FM
98.7FM / 1450AM WDLB - Timeless Classics
Listen Live: 107.5 THE ROCK92.7 FM
Family owned radio stations serving all of Central Wisconsin

Wisconsin Legislators Approve Accepting State's Share of Lawsuit Against Drug Manufacturers/Distributors

Wednesday, May 3rd, 2023 -- 11:00 AM

(AP) Wisconsin legislators decided Tuesday to accept the state’s share of a settlement stemming from another multistate lawsuit accusing drug manufacturers and distributors of contributing to the nation’s opioid crisis.

A coalition of states and local governments secured settlements in November and December with opioid manufacturers Teva and Allergan as well as with pharmaceutical chains Walmart, Walgreens and CVS totaling $19.2 billion.

Wisconsin is in line to receive about $324.3 million, with 30% going to the state and 70% going to county governments. The Legislature’s Joint Finance Committee approved a motion to accept the money during a meeting Tuesday.

Accepting the settlements will also subject the companies to a Wisconsin circuit court order requiring them to make major changes in how prescription opioids are sold and dispensed. Teva and Allergan have agreed to limit opioid marketing, promotion, sale and distribution.

The pharmacy chains will implement requirements addressing compliance structures and pharmacist judgment, according to documents prepared by the state Justice Department.

More than 3,000 lawsuits have been filed by state and local governments, Native American tribes, unions, hospitals and other entities in state and federal courts over the toll of opioids.

Most allege the industry created a public nuisance in a crisis that has been linked to the deaths of 500,000 Americans over the past two decades. Wisconsin entered similar settlements with four companies involved in the opioid industry, Johnson & Johnson, AmerisourceBergen, Cardinal Health and McKesson, in 2022.


Feel free to contact us with questions and/or comments.